FY2025 EPS Estimates for Alkermes Cut by Leerink Partnrs

Alkermes plc (NASDAQ:ALKS) – Research analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for Alkermes in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of $1.33 for the year, down from their previous forecast of $1.38. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Leerink Partnrs also issued estimates for Alkermes’ FY2026 earnings at $1.52 EPS and FY2028 earnings at $1.30 EPS.

ALKS has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft lifted their target price on Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, March 27th. StockNews.com upgraded Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. HC Wainwright reiterated a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a report on Thursday, February 13th. UBS Group upgraded shares of Alkermes from a “sell” rating to a “neutral” rating and boosted their price target for the company from $21.00 to $38.00 in a report on Tuesday, March 4th. Finally, Royal Bank of Canada began coverage on shares of Alkermes in a research note on Thursday, March 13th. They issued a “sector perform” rating and a $40.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.50.

Alkermes Stock Performance

Alkermes stock opened at $27.20 on Wednesday. The firm has a market cap of $4.48 billion, a price-to-earnings ratio of 12.53, a price-to-earnings-growth ratio of 2.20 and a beta of 0.39. Alkermes has a 1 year low of $22.90 and a 1 year high of $36.45. The firm’s 50 day moving average price is $32.91 and its two-hundred day moving average price is $30.43.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

Hedge Funds Weigh In On Alkermes

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP increased its stake in shares of Alkermes by 13.6% during the 4th quarter. RTW Investments LP now owns 7,557,835 shares of the company’s stock worth $217,363,000 after purchasing an additional 903,802 shares during the last quarter. Renaissance Technologies LLC increased its position in Alkermes by 1.1% during the fourth quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company’s stock worth $157,568,000 after buying an additional 57,697 shares during the last quarter. American Century Companies Inc. raised its holdings in Alkermes by 6.5% during the fourth quarter. American Century Companies Inc. now owns 3,450,707 shares of the company’s stock valued at $99,242,000 after buying an additional 209,740 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Alkermes by 4.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company’s stock worth $86,842,000 after buying an additional 128,701 shares during the last quarter. Finally, Avoro Capital Advisors LLC acquired a new stake in shares of Alkermes in the fourth quarter worth about $70,462,000. Institutional investors own 95.21% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Craig C. Hopkinson sold 100,918 shares of Alkermes stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the completion of the sale, the executive vice president now directly owns 44,290 shares in the company, valued at $1,419,494.50. The trade was a 69.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.89% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.